Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
Despite the development of targeted therapies, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) remain the cornerstone of treatment of rheumatoid arthritis (RA). A literature search was conducted on treatment recommendations and relevant papers regarding new insights on thera...
Guardado en:
Autores principales: | Ivan Padjen, Mirna Reihl Crnogaj, Branimir Anić |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e0bc9db1a4a145ef8336bc1ddecacc68 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
por: Zhang L, et al.
Publicado: (2020) -
A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis
por: Abdulkhaliq A, et al.
Publicado: (2021) -
Rheumatoid Arthritis Saudi Database (RASD): Disease Characteristics and Remission Rates in a Tertiary Care Center
por: Almoallim H, et al.
Publicado: (2020) -
Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients
por: Almalag H, et al.
Publicado: (2020) -
Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study
por: Morrison A, et al.
Publicado: (2021)